Drug Res (Stuttg) 2013; 63(05): 237-242
DOI: 10.1055/s-0033-1334924
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Investigation of the Pharmacokinetic Interaction between Ritonavir and CMDCK, a New Non-nucleoside Reverse Transcriptase Inhibitor

X.-M. Zhuang
1   Key laboratory of drug metabolism and pharmacokinetics, Beijing Institute of Pharmacology and Toxicology, Beijing, China
,
G.-L. Shen
1   Key laboratory of drug metabolism and pharmacokinetics, Beijing Institute of Pharmacology and Toxicology, Beijing, China
,
M. Yuan
1   Key laboratory of drug metabolism and pharmacokinetics, Beijing Institute of Pharmacology and Toxicology, Beijing, China
,
H. Li
1   Key laboratory of drug metabolism and pharmacokinetics, Beijing Institute of Pharmacology and Toxicology, Beijing, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 14. November 2012

accepted 01. Februar 2013

Publikationsdatum:
28. März 2013 (online)

Abstract

The aim of this study was to investigate the pharmacokinetic interaction between ritonavir (RTV) and an anti-HIV agent 3-cyanomethyl-4-methyl-DCK (CMDCK). CMDCK was administered orally (8 mg/kg) and intravenously (2 mg/kg) to rats in the absence or presence of RTV (1 or 2.5 mg/kg). By comparing the pharmacokinetic parameters between the control and the RTV treated groups, it was found that co-administration with RTV could significantly increase the plasma exposure of CMDCK, through improving the hepatic and intestinal availabilities. The AUCinf of CMDCK was increased by 2.4 or 8.7 times for intravenous or oral route, respectively. The oral bioavailability of CMDCK was increased from 15% of the control group to 45% of the RTV concomitant group (2.5 mg/kg). In the in vitro studies with liver and intestinal microsomes, the K i values of RTV on the CMDCK metabolism were determined and found to be 0.22 and 0.48 µM for human, 0.33 and 1.60 µM for rat, respectively. Caco-2 cells study showed that CMDCK is not a P-glycoprotein (P-gp) substrate and its transepithelial transport is mainly through passive diffusion. The in vitro and in vivo results indicate that RTV could improve the bioavailability of CMDCK by inhibiting CYP3A mediated metabolism in both liver and intestine.

 
  • References

  • 1 Reynolds C, de Koning CB, Pelly SC et al. In search of a treatment for HIV – current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chem Soc Rev 2012; 41: 4657-4670
  • 2 Huang F, Allen L, Huang DB et al. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther 2012; 37: 81-88
  • 3 Xie L, Guo HF, Lu H et al. Development and preclinical studies of broad-spectrum anti-HIV agent (3'R, 4'R)-3-cyanomethyl-4-methyl-3', 4'-di-O-(S)-camphanoyl- (+)-cis-khellact- one (3-cyanomethyl-4-methyl-DCK). J Med Chem 2008; 51: 7689-7696
  • 4 Zhuang XM, Deng JT, Li H et al. Metabolism of 3-cyanomethyl-4-methyl-DCK, a novel anti-HIV agent, in human liver microsomes and recombinant CYP enzymes. Acta Pharmacol Sin 2011; 32: 1276-1284
  • 5 Willams JA, Ring BJ, Cantrell VE et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-891
  • 6 MacGregor TR, Sabo JP, Norris SH et al. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 2004; 5: 371-382
  • 7 Li F, Wang L, Guo GL et al. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos 2010; 38: 871-878
  • 8 Scott JD. Simplifying the treatment of HIV infection with ritonavirboosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 2005; 62: 809-815
  • 9 Kumar S, Kwei GY, Poon GK et al. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-Glycoprotein. J Pharmacol Exp Ther 2003; 304: 1161-1171
  • 10 Cotreau MM, von Moltke LL, Harmatz JS et al. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome P450 induction by tamoxifen. Pharmacology 2001; 63: 210-219
  • 11 Petri N, Tannergren C, Rungstad Dd et al. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 2004; 21: 1398-1404
  • 12 Kong WL, Zhuang XM, Li H et al. A LC-MS/MS method for quantification of CMDCK, a novel anti-HIV agent in rat plasma and its application to a pharmacokinetic study. Chromatographia 2011; 73: 649-657
  • 13 Wu CY, Benet LZ, Hebert MF et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-497
  • 14 Ogasawara A, Kume T, Kazama E. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 2007; 35: 410-418
  • 15 Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I Clearance. Drug Metab Dispos 2004; 32: 603-611
  • 16 Zhang DL, Zhu MS, Humphreys WG. (eds.). Drug metabolism in drug design and development. (1st ed.) New Jersey: John Wiley & Sons, Inc.; 2008: 523-526
  • 17 Grimm SW, Einolf HJ, Hall SD et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009; 37: 1355-1370
  • 18 Komura H, Iwaki M. Species Differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2008; 97: 1775-1800
  • 19 Bjornsson TD, Callaghan JT, Einolf HJ et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-469
  • 20 van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-F99
  • 21 Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430-436